Alderley Park - Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that at the General Meeting of the Company held earlier today, all resolutions put to the meeting were duly passed.

As a consequence of the capitalisation of the loan agreement (the 'Loan') with Moulton Goodies Limited ('MGL') as announced on 31 December 2019, 52,030,789 new ordinary shares will be issued and allotted to MGL on 22 January 2020. At such point the Loan will have been discharged in full and cease to be a debt of the Company meaning there will be no requirement on the Company to repay the Loan or any other amount to MGL.

Following admission on 22 January 2020 of the 52,030,789 new ordinary shares and in accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, it will have 178,508,703 ordinary shares of 1p each in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in Redx will be 178,508,703. The International Identification Number ('ISIN') for Redx's ordinary shares is GB00BSNB6S51.

Contact:

Tel: +44 1625 469 920

About Redx Pharma Plc

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM: REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

(C) 2020 Electronic News Publishing, source ENP Newswire